Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. - Wikidata - awgldk - TriplyDB

Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.

Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.

http://www.wikidata.org/entity/Q36128894

about

Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies Dissecting the indirect effects caused by vaccines into the basic elements Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers.Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis Prospects for prevention of HPV-driven oropharynx cancer.The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.Papillomaviruses: Viral evolution, cancer and evolutionary medicine Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern Brazil Comparison of DNA testing strategies in monitoring human papillomavirus infection prevalence through simulation.Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.Why the time is right to tackle breast and cervical cancer in low-resource settings.Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.Society of behavioral medicine supports increasing HPV vaccination uptake: an urgent opportunity for cancer prevention.Dynamics of high-risk nonvaccine human papillomavirus types after actual vaccination scheme.Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.Herd protection effect of N95 respirators in healthcare workers.Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening.Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.Optimization of HPV DNA detection in urine by improving collection, storage, and extraction.HPV genotypes co-infections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes.Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women.Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity.Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.HPV prophylactic vaccines: lessons learned from 10 years experience Human Papillomavirus Vaccination: Making Sense of the Public Controversy

P2860

Q26770541-C473A620-8B21-46A2-9486-279E4F344A81 Q26799527-34BB8473-186F-4653-942A-E274139E05F3 Q26799574-E631463F-BC9C-4AD7-B126-28670BD48A98 Q28072364-168FD6C0-C511-4F3B-ABE5-6921F034EF84 Q28084924-5EC5A129-9BFB-4B11-B4AD-300AF247C0EE Q33759930-53775829-08E4-4020-A9A9-4F1829FEF193 Q34241823-3F8D08C7-9C1A-462B-9AE3-5E80AEA47228 Q35166924-D9E1F615-394E-4E97-B305-693384F4C1C2 Q35691927-26069792-4AB6-43AC-9D2B-26E94424D76B Q36184620-8F0D6B52-5F87-4C5F-BBEB-AD74357C7265 Q36231336-6E19C9ED-92E8-4726-80E2-ABA53040CBA2 Q36602973-2EA00BCD-CA66-4FC9-B65A-4142BA63C579 Q37214452-DDFA077F-1793-4FDC-877D-26FB2B591742 Q37288157-B8C64FC4-7C9D-4128-841C-3E4C4E471490 Q37416019-E1F6CF3C-9D37-4D8C-8FD4-B82B783D5F85 Q37718767-8DDE78F3-48E6-4E2C-9639-C8DAADB62E94 Q37840047-2CF7E4D4-E5B9-4061-B26A-D8894504F175 Q38984023-F55F20A9-D75A-4C17-B78F-CD1C65FD475C Q38993490-65DAF950-F970-4C29-AC17-9B59E844F169 Q39241406-2C632B58-4C44-4905-AD0F-F89859A85E52 Q40509494-6D7A7CFA-8C5A-4B3E-95D4-B103D32183B0 Q40647908-1050C727-CC75-455C-89B7-E0C3AD077330 Q40805660-F090A55B-5FCC-41A0-8648-40CCBB5EF6D6 Q41651390-DA5B5EC7-3121-40C2-96A6-B588BCF50BDC Q41933605-5976C110-CF41-4D35-91BA-9B7396EDFA78 Q42211075-F3E12F5C-B051-45B5-A81A-181F7D9603AB Q46257079-117862DE-0C5E-49B6-AA80-46A8EE72B0A8 Q46775905-91C677B6-D7FF-4A59-9175-9EAF84CD4FAA Q47363184-B7ADB349-2799-4CA9-87E5-3D8B62FD4D7D Q51872328-A905613D-35EE-46F7-9DA2-1B9ABC461005 Q56067928-753D102D-B687-40FC-86D0-8816D5B8827B Q57089326-C977BB5A-02D7-46CD-916A-4D1C2A3BFA43

P2860

Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.

http://www.wikidata.org/entity/Q36128894

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Vaccine-type human papillomavi ...... on after vaccine introduction.

@ast

Vaccine-type human papillomavi ...... on after vaccine introduction.

@en

type

label

Vaccine-type human papillomavi ...... on after vaccine introduction.

@ast

Vaccine-type human papillomavi ...... on after vaccine introduction.

@en

prefLabel

Vaccine-type human papillomavi ...... on after vaccine introduction.

@ast

Vaccine-type human papillomavi ...... on after vaccine introduction.

@en

P1433

Q36128894-702BF030-716B-4EB1-B1F2-778AE0793D7A

P1476

Q36128894-7E8AFB1A-D34E-4F07-A8B0-24E3C172D5A3

P2093

Q36128894-9AC3CD03-8928-47E0-AA55-934FA92F2156

Q36128894-A422800A-4302-4BA4-902B-ABF0EE7373CF

Q36128894-B9D4B6EC-3A93-45A7-911D-183F292E1537

Q36128894-C9316E99-EAA8-44D6-95C0-FD01552165BE

Q36128894-D5390B60-A851-458C-BD01-6C89D06DD6E8

Q36128894-D913F4E5-BF72-4796-96C3-F661D3E60FDB

P2860

Q36128894-06C27624-E211-4E8C-A668-36C0C60C7054

Q36128894-0858D657-8ACD-43C5-A420-EEEBBACC7209

Q36128894-19FE6871-A1BC-400E-8804-EABEC8404934

Q36128894-1CF2351A-7001-4044-8E60-E559C5FD1F67

Q36128894-30F04130-70D3-4DF7-B3AE-370203035E19

Q36128894-32C01470-4298-4AC9-82D2-F9CB8A4D41BF

Q36128894-3E152661-0200-457C-9125-A1C34A6A978C

Q36128894-4DBBD07E-0291-4129-A6ED-F30DDDC9E484

Q36128894-5B0B03D8-A959-49D5-9ABF-9DE72816790B

Q36128894-6DC5E325-44B3-4F36-BEF9-3E7C50A5A551

P304

Q36128894-9E6E6337-E395-4941-802C-835D5EA15C3C

P31

Q36128894-5C47AF0B-87BD-42A8-98A9-8C812C3A8557

P356

Q36128894-9286C185-A355-4377-B111-D94FA8D03D7C

P407

Q36128894-D9700579-70CB-4309-845E-E9857B821471

P433

Q36128894-6202372C-E8B5-4D42-9A8D-C31374699787

P478

Q36128894-ACB35EDB-6FED-4462-AE81-441BC8FEE9F8

P50

Q36128894-427B55A1-359C-4155-A8AD-E0B02CACCA80

P577

Q36128894-B133B4F1-74DD-43B9-A98A-34FECB7B0F8F

P5875

Q36128894-95DF85A4-4B27-4579-9A81-3510C6E5691C

P698

Q36128894-1D55B0F6-B4E9-40BA-8A84-D06B718A53A6

P932

Q36128894-1AE2AA3B-4E2C-4B2F-80CE-AE8CB2BDA4AB

P356

P1433

P1476

Vaccine-type human papillomavi ...... on after vaccine introduction.

@en

P2093

Darron R Brown

http://www.w3.org/2001/XMLSchema#string

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

Jessica A Kahn

http://www.w3.org/2001/XMLSchema#string

Lea E Widdice

http://www.w3.org/2001/XMLSchema#string

Lili Ding

http://www.w3.org/2001/XMLSchema#string

Susan Glynn

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)

FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

A review of human carcinogens--Part B: biological agents

Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Improved amplification of genital human papillomaviruses.

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

P304

e249-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2011-3587

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229015979

http://www.w3.org/2001/XMLSchema#string

P698

22778297

http://www.w3.org/2001/XMLSchema#string

P932

3408690

http://www.w3.org/2001/XMLSchema#string